目的应用超声造影技术(CEUS)探讨颈动脉狭窄斑块性质与缺血性脑血管事件的关系。方法选择颈内动脉狭窄(>70%)的患者24例,其中纳入狭窄处斑块45个作为研究对象。超声造影检测斑块内新生血管化情况,行头部MRI检查明确诊断,检测患者血清中甘油三酯、低密度脂蛋白等化验指标,并对其治疗前后的状态行NIHSS评分。分析颈内动脉狭窄处斑块内新生血管的增强程度与患者的临床症状、同侧脑梗死灶、血脂及预后等情况的关系。结果(1)有临床症状和无临床症状两组斑块内新生血管造影剂的增强强度比较(42.61±13.63VS 18.29±6.68,P<0.05),差异有显著统计学意义;(2)ICA狭窄同侧脑梗死组与非脑梗死组狭窄处斑块内的新生血管增强强度比较(34.66±13.67 VS 20.36±6.53,P<0.05),差异有显著统计学意义;(3)ICA狭窄处斑块内新生血管增强强度与并发高血压、糖尿病及血脂水平无统计学意义;(4)ICA狭窄处斑块内新生血管增强强度与治疗前NIHSS评分及治疗前后的NIHSS评分差值无明显相关性。结论 (1)有临床症状组ICA狭窄处斑块的新生血管增强强度明显高于无临床症状组;(2)ICA狭窄同侧的缺血性脑血管事件的发生与其狭窄处斑块内新生血管增强强度有相关性;(3)ICA狭窄处斑块内的新生血管增强强度与其高血压病病史、2型糖尿病病史、LDL和TG水平无明显相关性;(4)ICA狭窄处斑块内新生血管增强强度与治疗前NIHSS评分及治疗前后的NIHSS评分差值无明显相关性。
阿尔茨海默病(Alzheimer’s disease, AD)是一种对人类健康造成严重影响人类健康的神经退行性疾病。随着人口老龄化的加速,AD的发病率持续上升,给社会和家庭带来了巨大的负担。因此,寻找有效的治疗方案已成为一项重要的公共卫生挑战。在众多潜在治疗来源中,天然生物活性药物因其多途径靶向作用和低毒性而备受关注。中药在治疗AD方面具有独特的优势,尤其是石菖蒲因其开窍豁痰、醒神益智的功效,在临床上被广泛应用于AD等病证的治疗。奥拉西坦作为一种临床药物,已在AD治疗中得到应用,但其单独使用可能存在局限性。大量研究表明石菖蒲中的主要成分确实能够穿越血脑屏障进入大脑,并且与临床药物奥拉西坦联合使用时,可能增强药物的吸收效果,从而提升治疗效果。本文将重点讨论中药石菖蒲联合奥拉西坦在治疗阿尔茨海默病方面的研究进展,以期为阿尔茨海默病的治疗提供新的依据。Alzheimer’s disease (AD) is a neurodegenerative disease that seriously affects human health. With the acceleration of the aging of the population, the incidence rate of AD continues to rise, bringing a huge burden to society and families. Therefore, finding effective treatment options has become an important public health challenge. Among numerous potential therapeutic sources, natural bioactive drugs have attracted much attention due to their multi pathway targeting effects and low toxicity. Traditional Chinese medicine has unique advantages in the treatment of AD, especially Acorus tatarinowii Schott, which is widely used in clinical practice for the treatment of AD and other diseases due to its effects of opening the orifices, eliminating phlegm, awakening the mind, and improving intelligence. Olacetam, as a clinical drug, has been used in the treatment of AD, but its use alone may have limitations. Numerous studies have shown that the main components in Acorus tatarinowii Schott ca
